Efficacy and safety of pioglitazone in a phase 1/2 imatinib discontinuation trial (EDI‐PIO) in chronic myeloid leukemia with deep molecular response
Pagnano, Katia B.B., Lopes, Ana Beatriz P., Miranda, Eliana C., Delamain, Márcia T., Duarte, Gislaine O., Rodrigues, Bruna R.V., Povoa, Valquiria M.O., Furlin, Graziele C.P., Vianna, Jessica C., Silva, Matheus A.S., De Souza, Carmino A, De Paula, Erich V
Published in American journal of hematology (01.12.2020)
Published in American journal of hematology (01.12.2020)
Get full text
Journal Article